Clinical trials: Papillomavirus Vaccines
Human Papillomavirus-Related Carcinoma
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
Human papillomavirus (HPV) is a common sexually-transmitted virus which causes infections that usually last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx…
- Trial name
- NCT02568566
- Testing
- Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- 2 sites in United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Papillomavirus Vaccines, Human Immunodeficiency Virus
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection.
- Conditions
- Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology
- Trial name
- AGO-Gard (NCT05266898)
- Testing
- Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Genital Wart, Penile Cancer
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male…
- Conditions
- Genital Wart, Penile Cancer, Anal Cancer, PIN-1
- Trial name
- NCT06465914
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- 5 sites in China
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Human Papillomavirus Infection
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
This study will evaluate the tolerability and immunogenicity of administration of the first dose of V503 at the same time as Menactra™ and Adacel™ versus administration of V503 one month prior to administration of Menactra™ and…
- Trial name
- NCT00988884
- Testing
- V503, Comparator: Menactra™ (Concomitant), Comparator: Adacel™ (Concomitant)
- Volunteers
- 1,241 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Acceptability and Feasibility of Human Papilloma Virus Vaccine
The overall program goal is to determine the Acceptability and Feasibility of introducing a population based Human Papilloma Virus (HPV) Vaccination programme and understanding the key individual and community factors that would…
- Trial name
- NCT01209338
- Testing
- Health education
- Where
- India
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Hospital
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
The purpose of this study was to evaluate the safety, efficacy, and immunogenicity of V503 in comparison to GARDASIL. The primary hypotheses tested in the study were 1) V503 administered to 16- to 26-year-old adolescents and…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00543543
- Testing
- Comparator: GARDASIL, Experimental: V503
- Volunteers
- 14,840 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer
The purpose of the study is to assess the safety, tolerability and the HPV-specific immune responses of different doses of ISA101 vaccine with or without pegylated IFNα as combination therapy with carboplatin and paclitaxel.
- Trial name
- CervISA (NCT02128126)
- Testing
- ISA101/ISA101b
- Where
- 15 sites in Belgium, Germany and 1 more
- Volunteers
- 93 people
- Sponsor
- ISA Pharmaceuticals
Anal Cancer, Nonneoplastic Condition
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection.
- Conditions
- Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
- Trial name
- NCT01209325
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis
- Where
- 19 sites in United States, Puerto Rico
- Volunteers
- 149 people
- Sponsor
- AIDS Malignancy Consortium
Human Papillomavirus Vaccine
HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial
A randomized, observer-blind non-inferiority trial to evaluate alternative human papillomavirus (HPV) vaccination schedules in young females in West Africa.
- Trial name
- HPV (NCT03832049)
- Testing
- 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses, 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses, 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
- Where
- The Gambia
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Vaccination
"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake
This study will compare the use of informational videos only, personal story videos only, and the combination of both, to see which is most effective in increasing HPV vaccination.
- Trial name
- NCT06587243
- Testing
- Informational Animation Video, Personal Narrative Video
- Where
- United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Infections, Papillomavirus
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
This study will collect safety data of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in healthy females of Chinese origin who are unable to receive all three doses of commercially available HPV vaccine before…
- Trial name
- NCT00811798
- Testing
- Cervarix
- Where
- Hong Kong
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Late Complication From Kidney Transplant, Complication of Transplanted Liver
Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients
The human papilloma virus (HPV) is known to be an important cause of cervical and anal cancers. Studies on patients who have received a solid organ transplant (such as a liver or kidney transplant) have suggested the risk of…
- Conditions
- Late Complication From Kidney Transplant, Complication of Transplanted Liver, Human Papillomavirus-Related Carcinoma
- Trial name
- NCT02624349
- Testing
- Quadravalent human papillomavirus vaccine
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- The Hospital for Sick Children
Chronic Kidney Disease
Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease
People with chronic kidney disease are known to have immune response abnormalities, including a diminished response to some vaccinations.
- Trial name
- NCT00806676
- Testing
- Gardasil® Vaccine (FDA-approved vaccination regimen)
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- Johns Hopkins University
Human Papillomavirus Infection
A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age.
- Trial name
- NCT01984697
- Testing
- V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
- Volunteers
- 1,518 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus
Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine
The overall aim of this study is to further understand the memory response to HPV vaccination in subjects who have received 2 versus 3 doses of quadrivalent HPV vaccine.
- Trial name
- Merck08 (NCT02968420)
- Testing
- Human Papillomavirus 9-valent Vaccine, Recombinant
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Human Papillomavirus (HPV) Infection
Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children
This study will evaluate the safety and immune response of a single dose of a quadrivalent human papillomavirus (HPV) vaccine when given together with a tetanus-diphtheria (Td) vaccine in healthy children and adolescents aged 9…
- Trial name
- NCT07824310
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster
- Where
- Indonesia
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Palmar or Plantar Warts
Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts
Cutaneous viral warts are very common and are caused by the human papilloma virus (HPV). Most people experience warts in one form or another at some point in their lives. Cutaneous warts are related to different types of HPV.
- Trial name
- VAC-WARTS (NCT04814446)
- Testing
- Vaccination
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cervical Cancer, Genital Warts
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean…
- Trial name
- ADS (NCT02280642)
- Testing
- Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late
- Where
- 3 sites in United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- Duke University
HIV, Human Papillomavirus
Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults
The purpose of this study is to analyze and compare the immunogenicity of Bivalent and Tetravalent vaccines against Human Papillomavirus in HIV-infected adult persons.
- Trial name
- HIPAVAC (NCT01386164)
- Testing
- Gardasil, Cervarix
- Where
- Denmark
- Volunteers
- 92 people
- Sponsor
- University of Aarhus
Infections, Papillomavirus, Papillomavirus Vaccines
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control.
- Trial name
- NCT00294047
- Testing
- Cervarix
- Where
- 75 sites in United States, Australia and 10 more
- Volunteers
- 5,752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline